TPCW
INDV icon

TD Private Client Wealth’s Indivior Pharmaceuticals INDV Stock Holding History

TD Private Client Wealth’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81K Sell
2,657
-3,068
-54% -$101K ﹤0.01% 793
2025
Q4 		$205K Buy
5,725
+280
+5% +$8.55K ﹤0.01% 654
2025
Q3 		$131K Buy
+5,445
New +$114K ﹤0.01% 715

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TD Private Client Wealth's INDV Position: Q1 2026 in Review

TD Private Client Wealth reduced its Indivior Pharmaceuticals (INDV) stake by 54% in Q1 2026, selling an estimated $101K and leaving 2,657 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #793.

TD Private Client Wealth first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $205K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • TD Private Client Wealth held 2,657 shares of Indivior Pharmaceuticals worth $81K as of Q1 2026.
  • TD Private Client Wealth sold 3,068 Indivior Pharmaceuticals shares in Q1 2026, an estimated $101K.
  • Indivior Pharmaceuticals made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #793 holding.
  • TD Private Client Wealth first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • TD Private Client Wealth's Indivior Pharmaceuticals position peaked at $205K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.